Table 1. Summary of clinical data and statistical tests.

Statistically significant p < 0.05 values are shown in bold

NND: not normally distributed values, R(C)T: radio(chemo)therapy

Variables	Group A: pre-Covid-19	Group B: Covid-19	P-value (test)
Patients	47	47
Sex	33♂/14♀	36♂/11♀
Age	67.4 ± 10.6	69 ± 10.7
Tumor site
Oral cavity	5 (11%)	3 (6%)
Oropharynx	19 (40%)	28 (60%)
Larynx	19 (40%)	9 (19%)
Hypopharynx	4 (9%)	7 (15%)
SDI (weeks)			0.054 (Mann-Whitney-U-Test)
Median (Q1-Q3)	9.5 (4.5–20.5)	15 (6–27.1)
Mean ± SD	15.6 ± 16.8	20.5 ± 17.2
Range	0.5–75.5	1.8–77.4
DTI (weeks)			0.264 (Mann-Whitney-U-Test)
Median (Q1-Q3)	3 (2.2–4)	3.2 (2.2–4.7)
Mean ± SD	3.5 ± 2.7	3.8 ± 1.9
Range	0.7–19	09–10.6
TEI (weeks)			0.136 (Mann-Whitney-U-Test)
Median (Q1-Q3)	6.9 (6.1–10.6)	6.3 (5.7–10.6)
Mean ± SD	8.3 ± 3.1	7.8 ± 3
Range	2.9–15	2.3–12.6
T-stadium			0.668 (Pearson Chi-square-test)
Early T-stage (T1+T2)	31 (66%)	29 (62%)
Advanced T-stage (T3+T4)	16 (34%)	18 (38%)
N-Stadium			0.301 (Pearson Chi-square-test)
N-negative (N0)	24 (51%)	19 (40%)
N-positive (N1, N2, N3)	23 (49%)	28 (60%)
M-Stadium			0.022 (Pearson Chi-square-test)
No metastasis (M0)	47 (100%)	42 (90%)
Metastasis (M1)	0 (0%)	5 (10%)
Reconstructive surgery			0.007 (Pearson Chi-square-test)
No flap	22 (65%)	9 (31%)
Flap	12 (35%)	20 (69%)